Every one of those 1 sits in a single category, acquisition. Of the tracked stories, 1 of 1 also mention Lifeward Ltd, the most common co-covered peer. Each story carries 2 original sources on average, compared with 5.1 for the broader beat in this window.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Oramed Pharmaceuticals
Every one of those 1 sits in a single category, acquisition. Of the tracked stories, 1 of 1 also mention Lifeward Ltd, the most common co-covered peer. Each story carries 2 original sources on average, compared with 5.1 for the broader beat in this window. At 6, the average consequence score sits below the same-window beat average of 6.1. Oramed Pharmaceuticals appears in 1 tracked Healthcare story from March 13, 2026.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 27 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Oramed Pharmaceuticals. Shared-story counts are live from our verified record — not editorial picks.
Lifeward Ltd shareholders have officially approved a strategic partnership with Oramed Pharmaceuticals, signaling a major pivot toward becoming a diversified biomedical company. The deal integrates Lifeward's robotic rehabilitation technology with Oramed's pharmaceutical expertise to create a multi-disciplinary healthcare entity.